Efficacy of Multiple Drugs in Preventing Chronic Peripheral Neuropathy Induced by Platinum and Taxane: A Network Meta-analysis
10.3971/j.issn.1000-8578.2022.21.0675
- VernacularTitle:多种药物预防铂类和紫杉烷类致慢性周围神经病变有效性的网状Meta分析
- Author:
Cuilyu LIANG
1
;
Yin ZHANG
;
Qiying CHEN
;
Pingping ZHUO
Author Information
1. Department of Pharmacy, Second Affiliated Hospital, Fujian Medical University, Quanzhou 362000, China
- Publication Type:Research Article
- Keywords:
Chronic peripheral neuropathy;
Prevention;
Drug;
Network Meta-analysis
- From:
Cancer Research on Prevention and Treatment
2022;49(2):128-140
- CountryChina
- Language:Chinese
-
Abstract:
Objective To perform a network meta-analysis (NMA) for the efficacy of 11 drugs in preventing chronic peripheral neuropathy induced by platinum and taxane (PTIPN). Methods PubMed, Cochrane library, Embase, CNKI, WanFang database and VIP database were searched up to February 2021 for relevant randomized controlled trials (RCTs) addressing the drugs to prevent PTIPN. After extracting relevant data, Stata 14.0 and ADDIS 1.16.6 softwares were used for statistical analysis. Results A total of 70 studies involving 6201 patients were included. The results of network Meta-analysis showed that amifostine, ganglioside, Huangqi Guizhi Wuwu decoction (HQGZT), vitamin E, calcium and magnesium infusion and omega-3 fatty acids were superior to placebo or blank groups in reducing the incidence of overall or severe PTIPN. The rank probability plot and the SUCRA calculation results suggested that amifostine, HQGZT and omega-3 fatty acids were in first order. The differences between the 11 drugs and placebo or blank groups were not statistically significant, except for amifostine which was reported to aggravate the adverse reactions of nausea and vomiting and hypotension in patients. Conclusion HQGZT, Ganglioside, Vitamin E, omega-3 fatty acids, calcium and magnesium infusion and glutathione can reduce the occurrence of PTIPN, and HQGZT has the highest efficiency.
